Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
7,408.50
(
-1.24%
)
US TECH 100
28,244.40
(
-1.90%
)
Dow Jones
49,526.17
(
-1.07%
)
Brent Oil
106.70
(
0.00%
)
Bitcoin
78,425.88
(
-0.80%
)
News Focus
News Focus
Post# of 257579
Next 10
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122988
Boards Moderated 9
Alias Born 09/05/2002

DewDiligence

Member Level

Re: genisi post# 65635

Wednesday, 08/27/2008 9:57:54 AM

Wednesday, August 27, 2008 9:57:54 AM

Post# of 257579
Re: Apixaban dose

>These safety vs. efficacy results make me wonder if Apixaban's dose wasn't too low.<

You could be right. The Apixaban doses being tested in phase-3 for VTE treatment (as opposed to VTE prevention) are higher than the 2.5mg BID dose in the failed ADVANCE-1 trial. For instance, the AMPLIFY trial uses a loading dose of 10mg BID followed by a maintenance dose of 5mg BID (#msg-29928836).

Moreover, the phase-2 trial of Apixaban vs warfarin in VTE prevention employed doses of 5mg BID, 10mg BID, and 20mg qD (#msg-21044973).

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today